Neuropsychopharmacotherapeutic efficacy of XXXX in experimental paradigm of @entity72 .

@entity308 @entity146 @entity2438 @entity1505 @entity6108 @entity72 @entity148 @entity4207 @entity6929 @entity35 @entity67399 @entity528 @entity6137 @entity2383
AIM: Neuroinflammatory response triggered by the stimulation of matrix metalloproteinases plays a pivotal role in the development of @entity2438 phenotype. MMPs stimulate inflammatory cytokines release along with mitochondrial deficits that ultimately lead to @entity528 and precipitate @entity2438 symptoms. The aim of the present study was to explore the neuropsychopharmacotherapeutic efficacy of @entity6108 in the experimental paradigm of @entity72 . MATERIALS AND METHODS: 1M @entity6137 (4 l) was infused over 10min into the anterior portion of the caudoputamen to induce @entity146 in @entity35 . @entity6108 (50, 100 and 200mg/kg) was administered per orally starting from 2nd day of surgery and continued up to 28th day. @entity35 were tested for various neurobehavioural paradigms like social interaction, stereotypy, locomotor activity, @entity148 , novelty, @entity308 , @entity4207 as well as for repetitive and pervasive behavior. In addition, biochemical tests for oxidative stress, mitochondrial complexes, @entity1505 and @entity6929 were also carried out. KEY FINDINGS: Intracerebroventricular injection of @entity6137 produced neurological, sensory, behavioral, biochemical and molecular deficits which were assessed as endophenotype of @entity72 . Regular treatment with @entity6108 for four weeks significantly and dose dependently restored neurological, behavioral, biochemical and molecular changes associated with @entity2438 phenotype in @entity35 . SIGNIFICANCE: The major finding of the study is that @entity6108 restored the core and associated symptoms of @entity2438 phenotype by suppressing oxidative-nitrosative stress, @entity2383 , @entity1505 and @entity6929 in @entity67399 -induced @entity2438 in @entity35 . Therefore, @entity6108 can be developed as a potential neuropsychopharmacotherapeutic adjunct for @entity72 ( @entity72 ).
